AngioTarget         Angiostatic strategies for cancer therapy                  





The Company
























The Technology


Tumor growth is an active metabolic process requiring a continuous supply of nutrients and oxygen. This need is met by attraction of new vasculature. Inhibition of blood vessel formation is therefore a promising way of cancer treatment.


                                      Figure: A little tumor, 3x4 mm in size and grown in a

                                      preclinical animal model, attracting microvasculature

                                      from the host vascular bed for its growth.


The Angiogenesis Laboratory has a longterm interest in the relationship between angiogenesis and the immune system. Many mechanisms of interplay have been discovered. The main observation is that inhibition of angiogenesis reinforces the anti-tumor immune response. A double strike would be to induce an immune response to the tumor vasculature.


Cancer vaccines are beginning to pick up activity as evidenced by the success of recent proof-of-concept clinical trials. Vaccination against the tumor vasculature is an underestimated potential new tool for the treatment of cancer.


We use the highly specific and proprietary targets to raise an immune response by protein conjugation to potent antigens. This technology has shown to induce efficient antibody responses, leading to profound anti-tumor activities. 








© AngioVacs BV